scholarly journals Next-generation sequencing for cancer drug development: the present and visions for the future

2014 ◽  
Vol 11 (2) ◽  
pp. 139-142
Author(s):  
Scott M Kahn
Keyword(s):  
Next Generation Sequencing ◽  
Drug Development ◽  
Cancer Drug ◽  
Next Generation ◽  
The Future ◽  
Generation Sequencing

Target enrichment using capture probes: The future of HLA typing by next generation sequencing?

2015 ◽  
Vol 76 ◽  
pp. 165
Author(s):  
Hayley Hogan ◽  
Rhys Cransberg ◽  
Megan Jordan ◽  
Damian Goodridge ◽  
David Sayer
Keyword(s):  
Next Generation Sequencing ◽  
Hla Typing ◽  
Target Enrichment ◽  
Next Generation ◽  
The Future ◽  
Generation Sequencing

scholarly journals Tumor-Agnostic Drug Development

2018 ◽  
pp. 184-187 ◽  
Author(s):  
Michael Offin ◽  
Dazhi Liu ◽  
Alexander Drilon
Keyword(s):  
Next Generation Sequencing ◽  
Drug Development ◽  
Molecular Signatures ◽  
Patient Access ◽  
Next Generation ◽  
Basket Trial ◽  
Key Aspects ◽  
Tumor Types ◽  
Generation Sequencing

Therapies designed to target cancers that harbor specific molecular signatures have reshaped the landscape of oncologic drug development, and advances in next generation sequencing have led to an increase in the identification of these alterations across tumor types. Tumor-agnostic trial designs, such as the “basket trial,” have been developed as an approach to study the efficacy of these treatments and increase patient access, especially for patients whose tumors carry these alterations infrequently. We review key aspects of these genomically enriched trial strategies and their impact on drug development and approval.

Sign in / Sign up

Export Citation Format

Share Document